Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)

作者：Qianqian Zhu, Yanan Sun, Yingying Cui, Ke Ye, Chengliang Yang, Daoke Yang, Jie Ma, Xiao Liu, Jinming Yu, Hong Ge · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.14515 · 被引用次数：46 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Brain Metastases and Treatment

// Qianqian Zhu 1, * , Yanan Sun 1, * , Yingying Cui 1 , Ke Ye 1 , Chengliang Yang 1 , Daoke Yang 2 , Jie Ma 1 , Xiao Liu 1 , Jinming Yu 3 , Hong Ge 1 1 Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China 2 Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China 3 Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, 250117, Shandong Province, China * These authors contributed equally to this work Correspondence to: Hong Ge, email: gehong616@126.com Keywords: non-small cell lung cancer, brain metastases, epidermal growth factor receptor, tyrosine kinase inhibitors, radiotherapy Received: August 31, 2016      Accepted: December 27, 2016      Published: January 05, 2017 ABSTRACT This study compared treatment outcomes between TKI monotherapy and TKI administration combined with brain radiotherapy (TKI + RT) in 133 non-small cell lung cancer (NSCLC) patients with brain metastasis (BM). We also evaluated the association of different epidermal growth factor receptor (EGFR) mutation subtypes with treatment outcome. To screen for potential variables affecting cranial progression free survival (PFS) and overall survival (OS), we performed univariate and multivariate analysis based on Cox proportional-hazards models. Median cranial PFS and OS...